- Home
- DSS vs GNPX Comparison
DSS vs GNPX Comparison
Compare DSS & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- GNPX
- Stock Information
- Founded
- DSS 1984
- GNPX 2009
- Country
- DSS United States
- GNPX United States
- Employees
- DSS N/A
- GNPX N/A
- Industry
- DSS Containers/Packaging
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- GNPX Health Care
- Exchange
- DSS Nasdaq
- GNPX Nasdaq
- Market Cap
- DSS 7.3M
- GNPX 6.1M
- IPO Year
- DSS N/A
- GNPX 2018
- Fundamental
- Price
- DSS $0.85
- GNPX $0.75
- Analyst Decision
- DSS
- GNPX Strong Buy
- Analyst Count
- DSS 0
- GNPX 1
- Target Price
- DSS N/A
- GNPX $10.00
- AVG Volume (30 Days)
- DSS 31.9K
- GNPX 367.1K
- Earning Date
- DSS 11-13-2024
- GNPX 11-13-2024
- Dividend Yield
- DSS N/A
- GNPX N/A
- EPS Growth
- DSS N/A
- GNPX N/A
- EPS
- DSS N/A
- GNPX N/A
- Revenue
- DSS $25,019,000.00
- GNPX N/A
- Revenue This Year
- DSS N/A
- GNPX N/A
- Revenue Next Year
- DSS N/A
- GNPX N/A
- P/E Ratio
- DSS N/A
- GNPX N/A
- Revenue Growth
- DSS N/A
- GNPX N/A
- 52 Week Low
- DSS $0.81
- GNPX $0.28
- 52 Week High
- DSS $2.30
- GNPX $13.00
- Technical
- Relative Strength Index (RSI)
- DSS 41.29
- GNPX 40.74
- Support Level
- DSS $0.89
- GNPX $0.66
- Resistance Level
- DSS $0.99
- GNPX $0.74
- Average True Range (ATR)
- DSS 0.08
- GNPX 0.06
- MACD
- DSS -0.00
- GNPX 0.00
- Stochastic Oscillator
- DSS 0.00
- GNPX 35.04
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.